Background
Phase III RCT (FFCD 9102 — Fédération Francophone de Cancérologie Digestive). 444 eligible patients with operable T3N0-1M0 thoracic esophageal cancer (88.8% squamous cell carcinoma). All patients received initial CRT (2 cycles of cisplatin/5-FU concurrent with either conventional 46 Gy/4.5wk or split-course 2 × 15 Gy radiotherapy). Only patients who responded (n=259) were randomized to: surgery or continuation of additional CRT. Non-responders (not randomized) received additional CRT or supportive care.
Interventions and follow up
Arm A: Response-selected → esophagectomy (surgery)
Arm B: Response-selected → continuation of additional CRT (3 more cycles 5-FU/cisplatin + conventional 20 Gy or split-course 15 Gy)
Primary endpoint: Overall survival (2-year equivalence test)
mFollow up: Median 47.4 month
Arm B: Response-selected → continuation of additional CRT (3 more cycles 5-FU/cisplatin + conventional 20 Gy or split-course 15 Gy)
Primary endpoint: Overall survival (2-year equivalence test)
mFollow up: Median 47.4 month
Results
2-year OS: 34% (surgery) vs 40% (additional CRT), HR 0.90, P=.44 — equivalent
Median OS: 17.7 mo (surgery) vs 19.3 mo (additional CRT) — not significantly different
2-year local control rate: 66.4% (surgery) vs 57.0% (additional CRT)
3-month mortality: 9.3% (surgery) vs 0.8% (CRT), P=.002
Stent requirement: 5% (surgery) vs 32% (additional CRT), P<.001
Median OS: 17.7 mo (surgery) vs 19.3 mo (additional CRT) — not significantly different
2-year local control rate: 66.4% (surgery) vs 57.0% (additional CRT)
3-month mortality: 9.3% (surgery) vs 0.8% (CRT), P=.002
Stent requirement: 5% (surgery) vs 32% (additional CRT), P<.001
Adverse events
Main adverse events: Surgery arm: 9.3% 3-month mortality (high perioperative risk). Additional CRT arm: 32% required stent placement for dysphagia — significantly higher than surgery. Cumulative hospital stay: 68 days (surgery) vs 52 days (additional CRT). Overall survival equivalent despite higher surgical morbidity.
Conclusions
In patients with locally advanced thoracic esophageal cancer (predominantly SCC) who respond to initial chemoradiotherapy, continuation of definitive CRT provides equivalent survival compared to surgery, with lower treatment-related mortality. However, local control was better with surgery and the need for dysphagia management (stenting) was substantially higher with definitive CRT.
Key Limitations
Key Limitations: Enrolled mainly SCC (88.8%) — not applicable to adenocarcinoma. Design selects only CRT responders for randomization — the non-responders were not randomized, creating survivorship bias in the reported outcomes. Total radiation dose in the CRT arm included split-course RT which may be inferior to continuous-course RT in terms of local control. Surgery offered better local control at the cost of higher perioperative mortality. The high stent rate (32%) in the CRT arm reflects quality-of-life concerns not captured in OS alone.
Clinical Context
Together with the German Trial (Stahl 2005), FFCD 9102 established equivalence of definitive CRT and surgery-based trimodality therapy in SCC patients who respond to initial CRT. Both trials support organ-preservation as an alternative to esophagectomy in responding SCC patients. This concept underlies the NRG GI002 and other active watch-and-wait trials in esophageal SCC. A note on timing: the paper was published in JCO 2007 (print) though DOI includes "2005" — the study was conducted 1993–2000.
References
References: Bedenne L et al, J Clin Oncol 2007 (FFCD 9102)